BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients
|
|
- Cameron Jackson
- 8 years ago
- Views:
Transcription
1 BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients A. Al-Ansari 1, K. Al-Mawali 2, B. Al-Bahrani 3, M.S. Al-Moundhri 3 1 Department of Biology, College of Science, 2 Department of Pathology, College of Medicine and Health sciences, Sultan Qaboos University, Sultanate of Oman, 3 National Cancer Center of Royal Hospital, 4 Medical Oncology Unit, Department of Medicine, College of Medicine and Health sciences, Sultan Qaboos University, Sultanate of Oman Abstract Background: Breast cancer (BC) is the most common cancer reported in females in Oman and usually occurs at a relatively younger age, presents at an advanced stage and behaves aggressively. BC occurs in hereditary and sporadic forms. Although germ-line mutations in BRCA1 and BRCA2 genes are rare in sporadic cases compared with hereditary cases, molecular alterations, such as loss of heterozygosity, and CpG methylation, are common. In this study, we investigated the types of molecular alterations associated with hereditary and sporadic BRCA1-associated BC in Omani patients. Methods We obtained clinical data and samples from 43 sporadic BC patients. The selection of cases was made based on the following criteria: aged 40 years, or bilateral breast cancer, or estrogen and progesterone receptor negative status, and HER-2/neu negative (Triple Negative phenotype) status. Screening for Introduction Breast cancer (BC) is the most common cancer reported in females in Oman (1, 2). It develops relatively at a younger age, presents at an advanced stage, and is associated with a low survival rate (1, 2). Diagnosis of BC at a young age may be associated with various genetic Corresponding author: Prof. Mansour S. Al-Moundhri (FRACP, MRCP, MD), Professor and Consultant Medical Oncologist, Medical Oncology Unit, Department of Medicine, College of Medicine. Sultan Qaboos University, P.O. Box 35, postal code 123, Muscat, Oman mansours@squ.edu.om 45 molecular alterations was performed by direct sequencing, multiplex ligation-dependent probe amplification (MLPA). Results Genomic deletions and duplication in the BRCA1 gene were identified in four female patients. Two patients carried exon 1 and 2 deletions and two showed exon 1 and 2 duplication. Screening for mutation by direct sequencing revealed three polymorphisms in exon 11. Two of these polymorphisms are nonsynonymous (rs , rs799917) and one is synonymous (rs ). Conclusion The current pilot study detected previously described gene rearrangements and polymorphisms involving the BRCA1 gene and no seemingly pathogenic missense mutations were elucidated. Keywords BRCA1, breast cancer, mutation, polymorphism, Omani, Arab defects particularly, BRCA1 or BRCA2 gene mutations (3). Breast cancer occurs in hereditary and sporadic forms. Although germ-line mutations in BRCA1 and BRCA2 genes are rare in sporadic cases compared with hereditary cases, molecular alterations, such as loss of heterozygosity and CpG methylation, are common (4, 5). Published studies on BRCA1 or BRCA2 gene mutation in Arab populations remain very limited. El-Harith et al studied 29 Arab females and identified two mutations: a novel BRCA2 mutation
2 BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients A. Al-Ansari, et. al. (2482delGACT) and a BRCA1 mutation (Arg841Trp) (6). Kadouri et al studied 31 women of Palestinian Arab (PA) origin with BC with four of them having a significant family history suggestive of genetic predisposition (7). A novel BRCA1 mutation, E1373X in exon 12, was found in one patient (7). In this study, we investigated various BRCA1 molecular alterations associated with high risk sporadic BC in Omani patients. We have employed two techniques, direct DNA sequencing of BRCA1 exons and multiplex ligation-dependent probe amplification (MLPA), to screen for major genomic rearrangements. To the best of our knowledge, this is the first study from Oman and one of a few studies involving Arab populations. Therefore, the results will provide a better understanding of the molecular alterations associated with BC carcinogenesis in Arab populations. Materials and Methods Study subjects The study subjects consisted of high risk sporadic female BC patients who were diagnosed at Sultan Qaboos University Hospital. The selection of cases was made based on the following criteria: aged 40 years, or bilateral breast cancer, or estrogen and progesterone receptor negative status, and HER-2/neu negative (Triple Negative phenotype) status. Seven females had a family history of BC involving one first degree relative only but no patients had extensive family history of BC. The Medical Research and Ethics Committee of the College of Medicine of Sultan Qaboos University approved the study design. The study subjects gave informed consent prior to participation in the study. Genotyping method Ten milliliters of blood were collected in an EDTA tube and stored frozen until DNA extraction. DNA was extracted from whole blood using the commercially available QIAamp DNA blood Midi Kit (Qiagen, Germany) and stored until processed for genotyping. Analysis of the BRCA1 mutations was performed using polymerase chain reaction (PCR) and DNA sequencing. Genomic DNA from whole blood was used as the PCR template in a total reaction volume of 25 μl containing 10 pmol of primers designed for exons 3, 5, 11, 13, and 20 of BRCA1 genes as shown in Table 1. PCR was performed as follows: one cycle at 94 C for 5 min, 35 cycles at 94 C for 30 sec, 50 C for 30 sec, and 72 C for 30 sec, followed by 72 C for 5 min. PCR products were electrophoresed on a 2% agarose gel and visualized under ultraviolet light (UV) light after ethidium bromide staining. After checking the PCR products for the presence of amplified DNA, the samples were purified to be sequenced. The first 5 µl of the PCR products were transferred into 96-wells plates and 2 µl Table 1. Polymerase chain reaction primers, product sizes in base pairs, and annealing temperatures 46
3 of EXOSAP-IT were added to each well. The plates were covered with a heat-proof sticky lid and placed in a thermocycler with the following program: 37 C for 15 min and 80 C for 15 min for one cycle. The sequencing reaction was carried out after this step and was performed for both the forward and reverse directions in different tubes. Each tube contained 3 µl of MilliQ water, 1 µl of 3 pmol/µl of primers, 2 µl of BigDye buffer, 2 µl of BigDye terminator, and 2 µl of PCR Exosap products. We also tested BC cases using MLPA for genomic rearrangements. The commercially available P002 BRCA1 kit (MRC-Holland) was used for MLPA. Target DNA per 5 microliters ( ng) was denatured for 5 min at 98 C, after which 1.5 μl of the probe mix and 1.5 μl of MLPA buffer were added. The mixture was heated at 95 C for 1 min and incubated at 60 C overnight (16 h). Ligation was performed using Ligase-65 mix (32 μl) for 15 min at 54 C. Next, the ligase was inactivated by incubation for 5 min at 98 C. Ten microliters of this ligation mix was premixed with 30 μl of PCR buffer and placed in a PCR machine at 60 C. Subsequently, a 10-μl polymerase mix was added. PCR was conducted for 35 cycles (30 s at 95 C, 30 s at 60 C, and 60 s at 72 C). The fragments were analyzed on an ABI 3130 XL sequencer (Applied Biosystems) using Genescan-ROX 500 size standards (Applied Biosystems). Fragment analysis was performed using Genemarker software (v1.85, Demo). Results G. J. O. Issue 14, 2013 Clinical and pathological characteristics of patients Forty-three patients with a pathologically confirmed diagnosis of invasive BC were included. The mean age of all patients was 45.3 [standard deviation (SD), ±12.9] years. Most of the patients (65.1%) were pre-menopausal and 53.5% were aged 45 years. The mean clinical tumor size was 5.3 cm (±2.4 cm), whereas the mean pathological size was 3.9 cm (±2.8 cm). Axillary lymph nodes were found to be involved in 51.1% of patients who had surgical intervention (n=32). All patients had invasive ductal carcinoma except for two patients, each with lobular carcinoma and carcinosarcoma. Hormone receptor status was available for 40 patients and, among those, 24 (55.8%) and 24 (55.8%) patients expressed estrogen and progesterone receptors, respectively. Information regarding Her2/neu status was available for 30 patients, with three having Her2-positive disease. Thirty-six patients underwent surgical intervention and, of these, 20 patients (46.5%) had a mastectomy. Thirty-eight patients received chemotherapy either as neoadjuvant (10 patients) or adjuvant (28 patients) regimens. External beam radiotherapy was administered to 74.4% of patients (n=32). All patients who expressed hormone receptors received hormonal treatment (28 patients). At the time of analysis Table 2. BRCA1 polymorphisms detected in 43 high-risk patients 47
4 BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients A. Al-Ansari, et. al. (May 2012), 27 patients were alive, 13 died, and 3 were lost to follow-up. With a mean follow-up duration of 54 months, the mean survival time was 87.1 months [95% confidence interval (CI): months] and the median survival time was months (95% CI: months) with a 5-year survival rate of 77.5 %. BRCA1 gene rearrangement and polymorphisms Genomic deletions and duplication in BRCA1 were identified in four female cases. Two cases carried exon 1 and 2 deletions and two showed Figure 1. BRCA1 MLPA analysis results for normal samples, samples with BRCA1 deletion, and samples with BRCA1 duplication. Profiles corresponding to BRCA1 exons and control probes are obtained from the overlap of a normal sample (red) with a test sample (blue). Exons are indicated at the bottom of the figure refer to the BRCA1 exons recognized by each MLPA probe. Arrows mark the deleted BRCA1 exons. c indicates the control peaks resulting from the amplification of probes located in different chromosomes. 48
5 exon 1 and 2 duplication as shown in Figure 1. Interestingly, none of the four cases with genomic rearrangement was known to have a family history of BC, but two are young and the other two have a triple-negative status. Screening for BRCA1 mutation by direct sequencing revealed three polymorphisms in exon 11. Two of these polymorphisms are nonsynonymous (rs , rs799917) and one is synonymous (rs ) as shown in Table 2. Discussion MLPA has considerably facilitated the study of BRCA genomic rearrangements simply and efficiently (8). Using MLPA, we identified genomic deletions and duplications in BRCA1 in four female cases. Two cases harbored exon 1 and 2 deletions and two showed exon 1 and 2 duplication. Therefore, we report a BRCA1 deletion/duplication detection rate of 9.7% in this cohort of patients. Previously, an Italian study reported a rate of genomic rearrangements of the BRCA1 gene of 20% and suggested routine BRCA1 mutational analysis in patients with no family history (9). However, other studies reported lower rates of BRCA1 rearrangements. An American study that included 71 American families reported a rate of 8% of BRCA1 rearrangements, which is consistent with our study (10). Similarly, a French study reported a BRCA1 rearrangement rate of 9.6% when they found five gene rearrangements in 52 mutationnegative families (11). Rearrangements of the BRCA1 gene varied in the German population from 1.7% to 5.7% and appear to be lower than other populations (12-14). Overall, our results are consistent with other studies despite the differences in sample size and selection criteria. Several reports regarding different ethnic groups reported rearrangements involving BRCA1 exons 1 and 2 (9, 14-16). In our study, these alterations were found in non-familial cases; therefore, a pathogenic role cannot be assumed. Furthermore, these deletions were reported in Italian families with breast/ovarian cancer (9). Deletion of exons 1 and 2 are thought to result from recombination between sequences located in intron 2 of the pseudo-brca1 gene and the corresponding region of the BRCA1 gene (9, 16). 49 G. J. O. Issue 14, 2013 We also performed direct sequencing of BRCA1 exons 3, 5, 13, and 11, which constitute 60% of the entire gene. Screening for mutation by direct sequencing revealed three polymorphisms in exon 11. Two of these polymorphisms are nonsynonymous (rs and rs799917), and one is synonymous (rs ) as shown in Table 2. The single-nucleotide polymorphism found in exon 14 (rs ) results in a change from alanine to valine in codon 2466 (Ala2466Val). However, the Ala2466Val substitution conserves the chemical and physical proprieties at this site as both amino acids are aliphatic and nonpolar and, therefore, probably has no functional significance. In the present study, a missense mutation in BRCA1 (M1008I) was detected in one patient, a finding that has been reported previously in different populations. The M1008I missense mutation is a conservative mutation due to a G>A transition at nucleotide 3143 in exon 11 changing codon 1008 (ATG) encoding the nonpolar Met into ATA-encoding Ile, another nonpolar residue (17). This polymorphism has been classified as neutral and could be found in trans with a clearly deleterious BRCA1 mutation (18, 19). Therefore, this variation has been suggested to lack a deleterious effect on BRCA1 protein function (17). The BRCA1 Pro871variation is a common polymorphism and has a high variant allele frequency of 45% in the current study and about 36% in Caucasians as reported previously (20). The function of BRCA1 Pro871Leu has not been clearly elucidated. The breast and ovarian cancer risk predisposition of this polymorphism has been inconsistent (21, 22). Two studies observed an increased risk associated with the variant allele (22, 23). However, large case-control studies found no association between heterozygosity or homozygosity of the BRCA1 Pro871Leu polymorphism and the risk of breast and/or ovarian cancers (5, 21, 24). The current study is limited by it being a single-institution study and where small number of high risk patients was included. Therefore, the possibility that other mutations may exist in Arab Omani population and a larger study is required for validation. Moreover, confirmatory
6 BRCA1 gene Molecular Alterations in Omani Breast Cancer Patients A. Al-Ansari, et. al. tests such as RT-PCR or southern blotting are needed for confirmation of MLPA findings. In conclusion, the current pilot such study detected previously described gene rearrangements and polymorphisms involving BRCA1 and no seemingly pathogenic missense mutations were elucidated. An extension and validation of these preliminary results is highly warranted. Acknowledgements This project was supported by Sultan Qaboos University Fund. Author s contributions 1. Aliya Al-Ansari: Conduct and supervision of all molecular work and review of manuscript. 2. Kamla Al-Mawali: Technical support from department of pathology 3. Bassim Al-Bahrani: Involved in patient enrollment and review of manuscript. 4. Mansour Al-Moundhri: Originator of study concept and leader of funded research project and writing of manuscript. 1. Kumar S, Burney IA, Al-Ajmi A, Al-Moundhri MS. Changing trends of breast cancer survival in sultanate of oman. Journal of oncology. 2011;2011: Epub 2010/10/ Al-Moundhri M, Al-Bahrani B, Pervez I, Ganguly SS, Nirmala V, Al-Madhani A, et al. The outcome of treatment of breast cancer in a developing country-- Oman. Breast. 2004;13(2): Epub 2004/03/ Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012;118(2): Epub 2011/09/ De Sanjose S, Leone M, Berez V, Izquierdo A, Font R, Brunet JM, et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. International journal of cancer Journal international du cancer. 2003;106(4): Epub 2003/07/ Dombernowsky SL, Weischer M, Freiberg JJ, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(8): Epub 2009/08/ El-Harith el HA, Abdel-Hadi MS, Steinmann D, Dork T. BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi medical journal. 2002;23(6): Epub 2002/06/ Kadouri L, Bercovich D, Elimelech A, Lerer I, Sagi M, Glusman G, et al. A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC cancer. 2007;7:14. Epub 2007/01/20. References Veschi S, Aceto G, Scioletti AP, Gatta V, Palka G, Cama A, et al. High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2007;18 Suppl 6:vi Epub 2007/09/ Montagna M, Dalla Palma M, Menin C, Agata S, De Nicolo A, Chieco-Bianchi L, et al. Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ ovarian cancer families. Human molecular genetics. 2003;12(9): Epub 2003/04/ Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, et al. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer research. 1999;59(2): Epub 1999/02/ Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa- Lyonnet D, Frebourg T, et al. Rapid detection of novel BRCA1 rearrangements in high-risk breastovarian cancer families using multiplex PCR of short fluorescent fragments. Human mutation. 2002;20(3): Epub 2002/08/ Hofmann W, Gorgens H, John A, Horn D, Huttner C, Arnold N, et al. Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. Human mutation. 2003;22(1): Epub 2003/06/ Preisler-Adams S, Schonbuchner I, Fiebig B, Welling B, Dworniczak B, Weber BH. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in highrisk families of German origin. Cancer genetics and cytogenetics. 2006;168(1):44-9. Epub 2006/06/15.
7 G. J. O. Issue 14, Hartmann C, John AL, Klaes R, Hofmann W, Bielen R, Koehler R, et al. Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Human mutation. 2004;24(6):534. Epub 2004/11/ Swensen J, Hoffman M, Skolnick MH, Neuhausen SL. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Human molecular genetics. 1997;6(9): Epub 1997/09/ Puget N, Gad S, Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, et al. Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. American journal of human genetics. 2002;70(4): Epub 2002/03/ Distelman-Menachem T, Shapira T, Laitman Y, Kaufman B, Barak F, Tavtigian S, et al. Analysis of BRCA1/BRCA2 genes contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Familial cancer. 2009;8(2): Epub 2008/09/ Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ, et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. American journal of human genetics. 2004;75(4): Epub 2004/08/ Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, et al. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer research. 2005;65(21): Epub 2005/11/ Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer research. 2003;63(19): Epub 2003/10/ McGuire WP, 3rd. Current status of taxane and platinum-based chemotherapy in ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(10 Suppl):133s-5s. Epub 2003/05/ Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, et al. BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk. International journal of cancer Journal international du cancer. 2003;103(3): Epub 2002/12/ Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97(9): Epub 2003/04/ Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term followup and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991;9(7): Epub 1991/07/01. 51
Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers
J. Appl. Genet. 44(3), 2003, pp. 419-423 Short communication Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers Bohdan GÓRSKI,
More informationGenetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS -
Genetic Testing for Hereditary Breast and Ovarian Cancer - BRCA1/2 ANALYSIS - January 2005 SCIENTIFIC BACKGROUND Breast cancer is considered to be one of the most prevalent cancer in women. The overall
More informationName of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer
Name of Policy: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Policy #: 513 Latest Review Date: January 2014 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule,
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES BRCA GENETIC TESTING The purpose of this document is to provide guidance to providers enrolled in the Connecticut Medical Assistance Program (CMAP) on the requirements for
More informationBreast cancer and the role of low penetrance alleles: a focus on ATM gene
Modena 18-19 novembre 2010 Breast cancer and the role of low penetrance alleles: a focus on ATM gene Dr. Laura La Paglia Breast Cancer genetic Other BC susceptibility genes TP53 PTEN STK11 CHEK2 BRCA1
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationIMMEDIATE HOT LINE: Effective March 2, 2015
MEDICARE COVERAGE OF LABORATORY TESTING Please remember when ordering laboratory tests that are billed to Medicare/Medicaid or other federally funded programs, the following requirements apply: 1. Only
More informationMRC-Holland MLPA. Related SALSA MLPA probemix P091 CFTR: contains probes for the CFTR gene, related to chronic pancreatitis.
SALSA MLPA probemix P242-B3 Pancreatitis Lot B3-0215. As compared to version B2 (lot B2-1212), one flanking probe has been removed and four reference probes have been replaced. Hereditary Pancreatitis
More informationRapid Acquisition of Unknown DNA Sequence Adjacent to a Known Segment by Multiplex Restriction Site PCR
Rapid Acquisition of Unknown DNA Sequence Adjacent to a Known Segment by Multiplex Restriction Site PCR BioTechniques 25:415-419 (September 1998) ABSTRACT The determination of unknown DNA sequences around
More informationGenetic Testing for Susceptibility to Breast and Ovarian Cancer (BRCA1 and BRCA 2)
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. M issouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationpatient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer
patient guide BRCA1 and BRCA2 Genetic Testing for Hereditary Breast and Ovarian Cancer What is hereditary cancer? Cancer affects many people in the U.S.: breast cancer affects 1 in 8 women and ovarian
More informationChapter 8: Recombinant DNA 2002 by W. H. Freeman and Company Chapter 8: Recombinant DNA 2002 by W. H. Freeman and Company
Genetic engineering: humans Gene replacement therapy or gene therapy Many technical and ethical issues implications for gene pool for germ-line gene therapy what traits constitute disease rather than just
More informationNumber 12.04.516 Effective Date August 11, 2015 Revision Date(s) Replaces 2.04.133 (not adopted)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDI HISTORY Genetic Testing for CHEK2 Mutations for Breast Cancer Number 12.04.516
More informationMRC-Holland MLPA. Description version 12; 02-12-2012
SALSA MLPA probemix P083-C1 CDH1 Lot C1-0211. As compared to previous B1 version, new in version C1: two CDH1 probes and several reference probes have been replaced/added. In addition, the 88 and 96nt
More informationAppendix 2 Molecular Biology Core Curriculum. Websites and Other Resources
Appendix 2 Molecular Biology Core Curriculum Websites and Other Resources Chapter 1 - The Molecular Basis of Cancer 1. Inside Cancer http://www.insidecancer.org/ From the Dolan DNA Learning Center Cold
More informationThe Department of Vermont Health Access Medical Policy
State of Vermont Department of Vermont Health Access 312 Hurricane Lane, Suite 201 [Phone] 802-879-5903 Williston, VT 05495-2807 [Fax] 802-879-5963 www.dvha.vermont.gov Agency of Human Services The Department
More informationGenetic Testing for CHEK2 Mutations for Breast Cancer
Genetic Testing for CHEK2 Mutations for Breast Cancer Policy Number: 2.04.133 Last Review: 8/2015 Origination: 8/2015 Next Review: 8/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationData Analysis for Ion Torrent Sequencing
IFU022 v140202 Research Use Only Instructions For Use Part III Data Analysis for Ion Torrent Sequencing MANUFACTURER: Multiplicom N.V. Galileilaan 18 2845 Niel Belgium Revision date: August 21, 2014 Page
More informationAnalysis of the DNA Methylation Patterns at the BRCA1 CpG Island
Analysis of the DNA Methylation Patterns at the BRCA1 CpG Island Frédérique Magdinier 1 and Robert Dante 2 1 Laboratory of Molecular Biology of the Cell, Ecole Normale Superieure, Lyon, France 2 Laboratory
More informationHereditary Ovarian cancer: BRCA1 and BRCA2. Karen H. Lu MD September 22, 2013
Hereditary Ovarian cancer: BRCA1 and BRCA2 Karen H. Lu MD September 22, 2013 Outline Hereditary Breast and Ovarian Cancer (HBOC) BRCA1/2 genes How to identify What it means to you What it means to your
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationHiPer RT-PCR Teaching Kit
HiPer RT-PCR Teaching Kit Product Code: HTBM024 Number of experiments that can be performed: 5 Duration of Experiment: Protocol: 4 hours Agarose Gel Electrophoresis: 45 minutes Storage Instructions: The
More informationGene mutation and molecular medicine Chapter 15
Gene mutation and molecular medicine Chapter 15 Lecture Objectives What Are Mutations? How Are DNA Molecules and Mutations Analyzed? How Do Defective Proteins Lead to Diseases? What DNA Changes Lead to
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationContents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer
Contents Introduction: biology and medicine, two separated compartments What we need to know: - boring basics in DNA/RNA structure and overview of particular aspects of molecular biology techniques - How
More informationBecker Muscular Dystrophy
Muscular Dystrophy A Case Study of Positional Cloning Described by Benjamin Duchenne (1868) X-linked recessive disease causing severe muscular degeneration. 100 % penetrance X d Y affected male Frequency
More informationSICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE
AP Biology Date SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE LEARNING OBJECTIVES Students will gain an appreciation of the physical effects of sickle cell anemia, its prevalence in the population,
More informationForensic DNA Testing Terminology
Forensic DNA Testing Terminology ABI 310 Genetic Analyzer a capillary electrophoresis instrument used by forensic DNA laboratories to separate short tandem repeat (STR) loci on the basis of their size.
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: May 2015 Policy No: 02 Effective Date:
More informationBRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide
BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide What is Hereditary? Breast cancer is the most common cancer in women in the U.S. (it affects about 1 in 8 women). Ovarian
More informationUmm AL Qura University MUTATIONS. Dr Neda M Bogari
Umm AL Qura University MUTATIONS Dr Neda M Bogari CONTACTS www.bogari.net http://web.me.com/bogari/bogari.net/ From DNA to Mutations MUTATION Definition: Permanent change in nucleotide sequence. It can
More information6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review
Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,
More informationGENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP
GENETIC CONSIDERATIONS IN CANCER TREATMENT AND SURVIVORSHIP WHO IS AT HIGH RISK OF HEREDITARY CANCER? Hereditary Cancer accounts for a small proportion of all cancer or approximately 5-10% THE DEVELOPMENT
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): May 20, 2014 Effective Date: December 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationCloning Blunt-End Pfu DNA Polymerase- Generated PCR Fragments into pgem -T Vector Systems
Promega Notes Number 71, 1999, p. 10 Blunt-End Pfu DNA Polymerase- Generated PCR Fragments into pgem -T Vector Systems By Kimberly Knoche, Ph.D., and Dan Kephart, Ph.D. Promega Corporation Corresponding
More informationDNA Fingerprinting. Unless they are identical twins, individuals have unique DNA
DNA Fingerprinting Unless they are identical twins, individuals have unique DNA DNA fingerprinting The name used for the unambiguous identifying technique that takes advantage of differences in DNA sequence
More informationHow many of you have checked out the web site on protein-dna interactions?
How many of you have checked out the web site on protein-dna interactions? Example of an approximately 40,000 probe spotted oligo microarray with enlarged inset to show detail. Find and be ready to discuss
More informationPrimeSTAR HS DNA Polymerase
Cat. # R010A For Research Use PrimeSTAR HS DNA Polymerase Product Manual Table of Contents I. Description...3 II. III. IV. Components...3 Storage...3 Features...3 V. General Composition of PCR Reaction
More informationRecommendations for the management of early breast cancer
Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationCurriculum Vitae. Education: Italian Degree of Doctor in Biology, 1972, University of L Aquila (Italy)
Curriculum Vitae Name: Pasquale Battista Date and place of birth: 17 st October 1949, Pescara, ITALY Nationality: ITALIAN Married, 1 daughter Official address, phone and fax numbers: G. d Annunzio University
More informationCommon Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationBiotechnology and Recombinant DNA (Chapter 9) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College
Biotechnology and Recombinant DNA (Chapter 9) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Primary Source for figures and content: Eastern Campus Tortora, G.J. Microbiology
More informationGenetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service
Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Genetic Testing for BRCA1 and BRCA2 NMP136 Effective Date*: April 2004 Updated: September 2015 This National Medical Policy is subject to the terms in the
More informationBRCA in Men. Mary B. Daly,M.D.,Ph.D. June 25, 2010
BRCA in Men Mary B. Daly,M.D.,Ph.D. June 25, 2010 BRCA in Men Inheritance patterns of BRCA1/2 Cancer Risks for men with BRCA1/2 mutations Risk management recommendations for men with BRCA1/2 mutations
More informationBRCA1 and BRCA2. BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS
BRCA1 and BRCA2 BRCA1 and BRCA2 Clinician Guide KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS BRCA1 and BRCA2 Breast cancer is the most common cancer in women, diagnosed in
More informationPCR was carried out in a reaction volume of 20 µl using the ABI AmpliTaq GOLD kit (ABI,
Supplemental Text/Tables PCR Amplification and Sequencing PCR was carried out in a reaction volume of 20 µl using the ABI AmpliTaq GOLD kit (ABI, Foster City, CA). Each PCR reaction contained 20 ng genomic
More informationThe CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers.
The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. Irene Catucci 1,2,12, Paolo Verderio 3,12, Sara Pizzamiglio 3,12, Siranoush Manoukian 4, Bernard Peissel 4, Daniela Zaffaroni
More informationIntroduction. Preparation of Template DNA
Procedures and Recommendations for DNA Sequencing at the Plant-Microbe Genomics Facility Ohio State University Biological Sciences Building Room 420, 484 W. 12th Ave., Columbus OH 43210 Telephone: 614/247-6204;
More informationBRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls?
BRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls? Giovanni Luca Scaglione, PhD ------------------------ Laboratory of Clinical Molecular Diagnostics and Personalized Medicine, Institute
More informationCloning GFP into Mammalian cells
Protocol for Cloning GFP into Mammalian cells Studiepraktik 2013 Molecular Biology and Molecular Medicine Aarhus University Produced by the instructors: Tobias Holm Bønnelykke, Rikke Mouridsen, Steffan
More informationBreast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: 2.02.06 CATEGORY: Laboratory Test
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR, 10/15/15 PAGE: 1 OF: 12 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationHEREDITARY BRCA1. Faulty gene INFORMATION LEAFLET. How Do I Reduce My Risk?
HEREDITARY BREAST CANCER BRCA1 Faulty gene INFORMATION LEAFLET How Do I Reduce My Risk? Page 1 CONTENTS Part A 1 What is BRCA1 2 How does BRCA1 affect a person s risk of cancer? 3Testing for BRCA1 4Benefits
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationOffice of Population Health Genomics
Office of Population Health Genomics Policy: Protocol for the management of female BRCA mutation carriers in Western Australia Purpose: Best Practice guidelines for the management of female BRCA mutation
More informationDNA Sequence Analysis
DNA Sequence Analysis Two general kinds of analysis Screen for one of a set of known sequences Determine the sequence even if it is novel Screening for a known sequence usually involves an oligonucleotide
More informationBRCA and Breast/Ovarian Cancer -- Analytic Validity Version 2003-6 2-1
ANALYTIC VALIDITY Question 8: Is the test qualitative or quantitative? Question 9: How often is a test positive when a mutation is present (analytic sensitivity)? Question 10: How often is the test negative
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Kara J. Milliron, MS, CGC Certified Genetic Counselor Breast and Ovarian Cancer Risk Evaluation Program University of Michigan Comprehensive Cancer Center I am a contract genetic counselor with Informed
More informationImproved methods for site-directed mutagenesis using Gibson Assembly TM Master Mix
CLONING & MAPPING DNA CLONING DNA AMPLIFICATION & PCR EPIGENETICS RNA ANALYSIS Improved methods for site-directed mutagenesis using Gibson Assembly TM Master Mix LIBRARY PREP FOR NET GEN SEQUENCING PROTEIN
More information360 Master Mix. , and a supplementary 360 GC Enhancer.
Product Bulletin AmpliTaq Gold 360 Master Mix and 360 DNA Polymerase AmpliTaq Gold 360 Master Mix AmpliTaq Gold 360 DNA Polymerase 360 Coverage for a Full Range of Targets AmpliTaq Gold 360 Master Mix
More informationThe Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine
The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary
More informationGene Mapping Techniques
Gene Mapping Techniques OBJECTIVES By the end of this session the student should be able to: Define genetic linkage and recombinant frequency State how genetic distance may be estimated State how restriction
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationBiological Sciences Initiative. Human Genome
Biological Sciences Initiative HHMI Human Genome Introduction In 2000, researchers from around the world published a draft sequence of the entire genome. 20 labs from 6 countries worked on the sequence.
More informationPrevention GENEration. The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
הסיכוי שבסיכון PREVENTION GENERATION Prevention GENEration The Importance of Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (HBOC) We thank Prof. Ephrat Levy-Lahad Director, Medical
More informationGenetic Testing for Hereditary Breast/ Ovarian Cancer Syndrome (BRCA1/BRCA2)
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Genetic Testing for Hereditary Breast/ Ovarian Cancer Syndrome
More informationAdvances in RainDance Sequence Enrichment Technology and Applications in Cancer Research. March 17, 2011 Rendez-Vous Séquençage
Advances in RainDance Sequence Enrichment Technology and Applications in Cancer Research March 17, 2011 Rendez-Vous Séquençage Presentation Overview Core Technology Review Sequence Enrichment Application
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationTargeted. sequencing solutions. Accurate, scalable, fast TARGETED
Targeted TARGETED Sequencing sequencing solutions Accurate, scalable, fast Sequencing for every lab, every budget, every application Ion Torrent semiconductor sequencing Ion Torrent technology has pioneered
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationIntroduction To Real Time Quantitative PCR (qpcr)
Introduction To Real Time Quantitative PCR (qpcr) SABiosciences, A QIAGEN Company www.sabiosciences.com The Seminar Topics The advantages of qpcr versus conventional PCR Work flow & applications Factors
More informationOverview of testing for Lynch syndrome/hnpcc
Overview of testing for Lynch syndrome/hnpcc This overview provides detailed information about interpreting MSI/IHC testing and genetic testing for Lynch syndrome/hnpcc. It is intended to be a reference
More informationBreast Cancer Screening
Breast Cancer Screening Summary of the Clinical Practice Guideline September 2013 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate
More informationProcedures For DNA Sequencing
Procedures For DNA Sequencing Plant-Microbe Genomics Facility (PMGF) Ohio State University 420 Biological Sciences Building 484 W. 12th Ave., Columbus OH 43210 Telephone: 614/247-6204 FAX: 614/292-6337
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationGENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110
GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic
More informationGenolution Pharmaceuticals, Inc. Life Science and Molecular Diagnostic Products
Genolution Pharmaceuticals, Inc. Revolution through genes, And Solution through genes. Life Science and Molecular Diagnostic Products www.genolution1.com TEL; 02-3010-8670, 8672 Geno-Serum Hepatitis B
More informationDal germinale al somatico nella identificazione di tumori ereditari
Modena 18-19 novembre 2010 Dal germinale al somatico nella identificazione di tumori ereditari Laura Ottini Tendencies to develop cancer can be inherited Fletcher & Houlston, 2010 Cancer is a genetic disease
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationThe Techniques of Molecular Biology: Forensic DNA Fingerprinting
Revised Fall 2011 The Techniques of Molecular Biology: Forensic DNA Fingerprinting The techniques of molecular biology are used to manipulate the structure and function of molecules such as DNA and proteins
More informationCommonly Used STR Markers
Commonly Used STR Markers Repeats Satellites 100 to 1000 bases repeated Minisatellites VNTR variable number tandem repeat 10 to 100 bases repeated Microsatellites STR short tandem repeat 2 to 6 bases repeated
More informationPNA BRAF Mutation Detection Kit
- PNA BRAF Mutation Detection Kit Catalog Number KA2102 50 tests/kit Version: 01 Intended for research use only www.abnova.com Introduction and Background Intended use The PNA BRAF Mutation Detection Kit
More informationUsing Digital Photography to Supplement Learning of Biotechnology. Methods
RESEARCH ON LEARNING Using Digital Photography to Supplement Learning of Biotechnology Fran n orf l u s AbstrAct The author used digital photography to supplement learning of biotechnology by students
More informationHepatitis B Virus Genemer Mix
Product Manual Hepatitis B Virus Genemer Mix Primer Pair for amplification of HBV Specific DNA Fragment Includes Internal Negative Control Primers and Template Catalog No.: 60-2007-12 Store at 20 o C For
More informationGenetic information (DNA) determines structure of proteins DNA RNA proteins cell structure 3.11 3.15 enzymes control cell chemistry ( metabolism )
Biology 1406 Exam 3 Notes Structure of DNA Ch. 10 Genetic information (DNA) determines structure of proteins DNA RNA proteins cell structure 3.11 3.15 enzymes control cell chemistry ( metabolism ) Proteins
More informationSingle-Cell Whole Genome Sequencing on the C1 System: a Performance Evaluation
PN 100-9879 A1 TECHNICAL NOTE Single-Cell Whole Genome Sequencing on the C1 System: a Performance Evaluation Introduction Cancer is a dynamic evolutionary process of which intratumor genetic and phenotypic
More informationGENOTYPING ASSAYS AT ZIRC
GENOTYPING ASSAYS AT ZIRC A. READ THIS FIRST - DISCLAIMER Dear ZIRC user, We now provide detailed genotyping protocols for a number of zebrafish lines distributed by ZIRC. These protocols were developed
More informationBRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study
The Breast (2007) 16, 280 292 THE BREAST www.elsevier.com/locate/breast ORIGINAL ARTICLE BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study
More informationImpact of radiation therapy on survival in patients with triple negative breast cancer
548 Impact of radiation therapy on survival in patients with triple negative breast cancer LAUREN T. STEWARD 1, FENG GAO 2, MARIE A. TAYLOR 3 and JULIE A. MARGENTHALER 1 1 Department of Surgery; 2 Division
More informationClinical Significance of Large Rearrangements in BRCA1 and BRCA2
Original Article Clinical Significance of Large Rearrangements in BRCA1 and BRCA2 Thaddeus Judkins, BS; Eric Rosenthal, PhD; Christopher Arnell, MBA; Lynn Anne Burbidge, BS; Wade Geary, BA; Toby Barrus,
More informationSpeed Matters - Fast ways from template to result
qpcr Symposium 2007 - Weihenstephan Speed Matters - Fast ways from template to result March 28, 2007 Dr. Thorsten Traeger Senior Scientist, Research and Development - 1 - Overview Ạgenda Fast PCR The Challenges
More informationDevelopment of a Workflow to Detect Sequence Variants in the BRCA1 and BRCA2 Genes
Your Innovative Research BRCA1 and BRCA2 Variant Detection Development of a Workflow to Detect Sequence Variants in the BRCA1 and BRCA2 Genes The oncogenetics group in the DNA Diagnostics division of the
More informationUnderstanding Hereditary Breast and Ovarian Cancer. Maritime Hereditary Cancer Service
Understanding Hereditary Breast and Ovarian Cancer Maritime Hereditary Cancer Service General Information Cancer is very common. About one in three (33%) people are diagnosed with some form of cancer during
More informationApplication Guide... 2
Protocol for GenomePlex Whole Genome Amplification from Formalin-Fixed Parrafin-Embedded (FFPE) tissue Application Guide... 2 I. Description... 2 II. Product Components... 2 III. Materials to be Supplied
More informationFocusing on results not data comprehensive data analysis for targeted next generation sequencing
Focusing on results not data comprehensive data analysis for targeted next generation sequencing Daniel Swan, Jolyon Holdstock, Angela Matchan, Richard Stark, John Shovelton, Duarte Mohla and Simon Hughes
More information